Co-Diagnostics

Co-Diagnostics Pre-Tax Margin

The Pre-Tax Profit Margin of Co-Diagnostics (CODX) as of Nov 20, 2026 is -7,793.22 %. In the previous year, Pre-Tax Profit Margin was -959.90 % — a change of 711.88% (lower).

Pre-Tax Margin

-7,793.22 %

YoY

711.88%

Last updated:

Pre-Tax Profit Margin of Co-Diagnostics is 2025 -7,793.22 % . Pre-Tax Profit Margin of Co-Diagnostics was 2024 -959.90 % . It decreases by 711.88% lower compared to the previous year.

The Co-Diagnostics Pre-Tax Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Pre-Tax Margin
Date
Pre-Tax Margin
Jan 1, 2018
-15,714.27 USD
Jan 1, 2019
-2,882.00 USD
Jan 1, 2020
57.10 USD
Jan 1, 2021
46.62 USD
Jan 1, 2022
-55.08 USD
Jan 1, 2023
-559.46 USD
Jan 1, 2024
-959.90 USD
Jan 1, 2025
-7,793.22 USD
The Co-Diagnostics Pre-Tax Margin history
YEARPre-Tax MarginYoY
-7,793.22 %+711.88%
-959.90 %+71.58%
-559.46 %+915.73%
-55.08 %-218.14%
46.62 %-18.35%
57.10 %-101.98%
-2,882.00 %-81.66%
-15,714.27 %-82.70%
-90,827.88 %+344.54%
-20,431.68 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Co-Diagnostics Stock analysis

What does Co-Diagnostics do? Co-Diagnostics, Inc. develops and sells diagnostic tests using proprietary reagents and a test design system for diseases and pathogens including tuberculosis, drug-resistant tuberculosis, hepatitis B and C, malaria, dengue, HIV, and Zika virus. The company also markets self-contained lab systems (MDx devices) from other manufacturers. Its products are sold to laboratories and healthcare providers for molecular testing of organisms and genetic diseases, automating complex procedures in test development and administration. The firm generates revenue through the sale of diagnostic reagents, validated tests, and MDx devices. The company's diagnostic technology focuses on nucleic acid detection and analysis, enabling molecular testing for various pathogens and genetic conditions. Its proprietary system allows for the design and validation of tests in-house, which are then marketed to healthcare institutions. Revenue streams include reagent sales, test kits, and equipment from partner manufacturers. Co-Diagnostics, Inc. targets laboratories and healthcare providers as key customers for its diagnostic solutions. The firm's products are designed to streamline molecular testing processes, reducing the complexity of traditional methods. This approach supports the company's revenue model based on direct sales of its proprietary tests and complementary equipment. Co-Diagnostics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Co-Diagnostics stock

Pre-Tax Profit Margin of Co-Diagnostics is -7,793.22 % in 2025.

Pre-Tax Profit Margin of Co-Diagnostics changed from -959.90 % to -7,793.22 %, representing a 711.88% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Pre-Tax Profit Margin Co-Diagnostics since 2006 – with annual values, charts, and detailed analysis.

Pre-tax margin measures the percentage of revenue remaining after all expenses except income taxes. It isolates operational and financial performance from tax effects.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Pre-Tax Profit Margin's Co-Diagnostics with sector peers and the industry average to assess whether it is attractive.

To evaluate Pre-Tax Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Pre-Tax Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Co-Diagnostics

All Key Metrics — Co-Diagnostics